Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL10424820 | 0.97 | KDM4E (0.39) | KDM4EGABRR1CACNA2D1CACNB3CACNA1C | |
| Hydrochloric Acid SCHEMBL2677291 | 0.97 | KDM4E (0.44) | KDM4EGABRR1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL22412936 | 0.83 | GABRR1 (0.48) | KDM4EGABRR1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL1572815 | 0.79 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL27945262 | 0.79 | TSHR (0.36) | ADRA1ATSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL5369984 | 0.79 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL5322047 | 0.77 | GABRR1 (0.36) | KDM4EGABRR1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL751650 | 0.77 | RNPEP (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL249850 | 0.77 | TSHR (0.39) | GABRR1CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL28450914 | 0.77 | CYP2C9 (0.35) | TSHRALDH1A1CYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116381072-B | Biomarker for identifying sporadic gout and frequent gout and application thereof | 苏州艾麦锶生命科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118011003-A | Biomarker composition for diagnosing gastric cancer and application thereof | 哈尔滨脉图精准技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230312967-A1 | WATER-BASED INK COMPOSITION FOR WRITING INSTRUMENTS, WRITING INSTRUMENT, AND CARTRIDGE INK FOR WRITING INSTRUMENTS | KABUSHIKI KAISHA PILOT CORPORATION (ALSO TRADING AS PILOT CORPORATION) (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4206291-A1 | INK COMPOSITION FOR WRITING IMPLEMENT, WRITING IMPLEMENT, AND CARTRIDGE INK FOR WRITING IMPLEMENT | Kabushiki Kaisha Pilot Corporation (also trading as Pilot Corporation) (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-116075563-A | Aqueous ink composition for writing instrument, and pen core ink for writing instrument | 株式会社百乐 | 2023-05-05 | — | — | CN | disclosed |
| US-20220031597-A1 | TOPICAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOF | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-11166938-B2 | External composition containing ascorbic acid and/or salts thereof | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20210052481-A1 | EXTERNAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOF | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| WO-2020067132-A1 | TOPICAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOF | ロート製薬株式会社 | 2020-04-02 | — | — | WO | disclosed |
| US-20190151284-A1 | EXTERNAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALTS THEREOF | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| CN-109414394-A | Topical composition containing ascorbic acid and/or its salt | 日本乐敦制药株式会社 | 2019-03-01 | — | — | CN | disclosed |
| CN-101677931-B | Wrinkling-preventing and -modifying agent | SHISEDO CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102762541-A | Diaza derivatives as modulators of chemokine receptors | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| JP-2010248211-A | COMPOSITION FOR ENHANCING COLLAGEN SYNTHESIS | ROHTO PHARMACEUT CO LTD | 2010-11-04 | — | — | JP | disclosed |
| US-20060263399-A1 | Preparation for external use on skin | VIVIER CANADA INC. (CA) | 2006-11-23 | — | — | US | disclosed |
| US-20060039961-A1 | Percutaneous absorption accelerator | VIVIER CANADA INC. (CA) | 2006-02-23 | — | — | US | disclosed |
| US-20060030621-A1 | Preparation for external use on skin | VIVIER CANADA INC. (CA) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039961-A1 | Percutaneous absorption accelerator | TPSG1, TPSB2, TPSD1 | KDM4E 4223/4885GABRR1 4115/4885CACNA2D1 4364/4885 |
| US-11166938-B2 | External composition containing ascorbic acid and/or salts thereof | TTPA, PROC, LRAT | KDM4E 3253/4885GABRR1 3817/4885CACNA2D1 3243/4885 |
| US-20060263399-A1 | Preparation for external use on skin | CUTA, SLC6A12, PROC | KDM4E 4226/4885GABRR1 2597/4885CACNA2D1 3980/4885 |
| US-20060030621-A1 | Preparation for external use on skin | FUCA2, LIPA, PROC | KDM4E 4374/4885GABRR1 4362/4885CACNA2D1 3918/4885 |
| US-20210052481-A1 | EXTERNAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOF | SLC6A12, PROC, EBP | KDM4E 3990/4885GABRR1 2114/4885CACNA2D1 2247/4885 |
| US-20190151284-A1 | EXTERNAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALTS THEREOF | TTPA, PROC, LRAT | KDM4E 3253/4885GABRR1 3817/4885CACNA2D1 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.